相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。European cancer mortality predictions for the year 2016 with focus on leukaemias
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2016)
Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma A 2015 Update
Ping Tang et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
Stefania Gori et al.
PLOS ONE (2016)
An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013
Kota Katanoda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
Wen-Dong Bai et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer
Siqi Han et al.
MABS (2014)
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models
Luigi Formisano et al.
BREAST CANCER RESEARCH (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells
Kazuhiko Shien et al.
CANCER RESEARCH (2013)
Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Brent N. Rexer et al.
CLINICAL CANCER RESEARCH (2013)
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
M. S. N. Mohd Sharial et al.
ANNALS OF ONCOLOGY (2012)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Promising molecular targeted therapies in breast cancer
Radha Munagala et al.
INDIAN JOURNAL OF PHARMACOLOGY (2011)
Trastuzumab resistance: all roads lead to SRC
Senthil K. Muthuswamy
NATURE MEDICINE (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
Ultan McDermott et al.
CANCER RESEARCH (2010)
Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells
Samuel Seoane et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
S. Chandarlapaty et al.
ONCOGENE (2010)
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment
Michael Hubalek et al.
WIENER MEDIZINISCHE WOCHENSCHRIFT (2010)
Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing
Timothy E. Kute et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
Aleix Prat et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
EK Rowinsky
ANNUAL REVIEW OF MEDICINE (2004)
Src family kinases, key regulators of signal transduction
SJ Parsons et al.
ONCOGENE (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
